Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA HCT vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension (to lower blood pressure, either as initial therapy or in patients not adequately controlled on monotherapy)
Hypertension
Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Aliskiren: terminal half-life 24-31 hours (accumulation supports once-daily dosing). Hydrochlorothiazide: 6-15 hours (correlates with duration of action).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Aliskiren is primarily metabolized by CYP3A4; Hydrochlorothiazide is not metabolized and excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Aliskiren: 78-91% unchanged in feces via biliary excretion, <2.4% in urine. Hydrochlorothiazide: ≥95% renal, 50-75% unchanged.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Aliskiren: 47-51% (albumin). Hydrochlorothiazide: 40-68% (albumin).
~90%, primarily to albumin
Aliskiren: 0.65-2.3 L/kg (extensive tissue distribution due to lipophilicity). Hydrochlorothiazide: 3-7 L/kg (distributes into erythrocytes).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Aliskiren: 2-5% oral (1.6-2.8% at 300 mg). Hydrochlorothiazide: 65-70% oral.
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in patients with GFR <30 m L/min/1.73m2. For GFR 30-59 m L/min/1.73m2: no dose adjustment required, but monitor serum potassium and creatinine. Discontinue if progressive oliguria or acute renal failure occurs.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: use with caution; no specific dose guidelines.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients less than 18 years of age.
Not recommended for pediatric use; safety in children under 12 years not established.
Elderly patients may be more sensitive to hypotension and electrolyte imbalances. Start at the lowest dose (150/12.5 mg) and titrate cautiously. Monitor renal function and electrolytes regularly.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Avoid use in pregnancy (especially 2nd and 3rd trimesters) due to fetal toxicity; discontinue immediately if pregnancy occurs.,Not recommended with ACE inhibitors or ARBs in patients with diabetes or renal impairment (Cr Cl < 60 m L/min) due to increased risk of renal dysfunction, hyperkalemia, and hypotension.,Symptomatic hypotension may occur, especially in volume-depleted patients; correct volume depletion before use.,Electrolyte imbalances: monitor serum potassium (risk of hyperkalemia), sodium, and magnesium; hydrochlorothiazide may cause hypokalemia, hyponatremia, and hypomagnesemia.,Renal impairment: monitor renal function; may cause acute renal failure; contraindicated with Cr Cl < 30 m L/min for hydrochlorothiazide component.,Angioedema may occur; discontinue if develops.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Pregnancy (risk of fetal harm),Anuria (due to hydrochlorothiazide component),Concomitant use with ACE inhibitors or ARBs in patients with diabetes mellitus or moderate-to-severe renal impairment (Cr Cl < 60 m L/min),Hypersensitivity to any component (including sulfonamide-derived drugs for hydrochlorothiazide)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and potassium-containing salt substitutes. Limit sodium intake to assist antihypertensive effect. Grapefruit juice may reduce aliskiren absorption; avoid concurrent consumption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossification defects. Second and third trimesters: Exposure is associated with fetal hypotension, anuria, renal failure, oligohydramnios, skull hypoplasia, and death. Hydrochlorothiazide: Crosses the placenta; risk of electrolyte disturbances, jaundice, and thrombocytopenia in the newborn. Generally avoid in pregnancy, especially second and third trimesters.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Aliskiren: Not known if excreted in human milk. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio not reported. Use with caution, monitor infant for dehydration, electrolyte imbalance. Consider alternatives if possible.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Avoid use during pregnancy. If exposure occurs, discontinue as soon as possible. No recommended dose adjustments; alternative agents are preferred. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, renal clearance) may reduce drug efficacy, but no specific dose adjustment studies exist for this combination.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Tekturna HCT is a fixed-dose combination of aliskiren (renin inhibitor) and hydrochlorothiazide (thiazide diuretic). Avoid use in pregnancy (category D). Monitor renal function and serum electrolytes, especially potassium and sodium, as aliskiren can increase potassium and HCTZ can cause hypokalemia. Contraindicated with concomitant use of ARBs or ACE inhibitors in patients with diabetes or renal impairment (e GFR <60 m L/min/1.73 m²). Assess for hypotension, especially in volume-depleted patients. Max antihypertensive effect may take 2-4 weeks.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid potassium supplements, salt substitutes, or high-potassium foods without consulting your doctor.,Take exactly as prescribed; do not skip doses or double up.,May cause dizziness; avoid driving until you know how the medication affects you.,Drink adequate fluids to prevent dehydration, especially in hot weather or with exercise.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion.,Avoid alcohol as it may increase blood pressure-lowering effects and dizziness.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA HCT vs ALDORIL 15, answered by our medical review team.
TEKTURNA HCT is a Antihypertensive combination that works by Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA HCT and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA HCT is: Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA HCT and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA HCT is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossificati. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.